科特里莫克萨和针对性抗生素预防跨直肠前列腺活检:一个单中心研究
Matthias Jahnen1, Thomas Amiel2, Florian Kirchoff2
1Department of Urology, Klinikum Rechts der Isar, School of Medicine and Health, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany. matthias.jahnen@tum.de.
World journal of urology
|April 25, 2024
概括
科特里莫克萨是跨直肠前列腺活检 (TRPB) 中抗生素预防的可行选择,当多抗性格拉姆阴性缺席时. 这项研究发现,科特里莫克萨不会增加TRPB患者感染并发症的风险.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 欧盟委员会对诺基诺的限制造成了对跨直肠前列腺活检 (TRPB) 的替代抗生素预防 (PAP) 的需求.
- 前列腺癌 (PCa) 诊断依赖于TRPB,需要有效的感染预防策略.
- 对TRPB中PAP进行cotrimoxazole的安全性和疗效的评估至关重要.
研究的目的:
- 研究可行性和有效性,作为一个实用的抗生素预防 (PAP) 转直肠前列腺活检 (TRPB).
- 评估与其他疗法相比,与科特里莫克萨PAP相关的传染性并发症率.
主要方法:
- 分析了一组697名为疑似前列腺癌 (PCa) 接受TRPB治疗的患者.
- 患者接受了科特里莫克萨PAP或基于查多耐药格拉姆阴性菌的向预防治疗.
- 感染并发症,微生物学发现和临床数据使用多变量逻辑回归来评估.
主要成果:
- 感染性并发症发生在2.6%的患者中;发烧是最常见的症状.
- 在具有阳性血液培养的患者的血液培养中发现了耐科特里莫克萨的大肠杆菌菌株.
- 多变量分析显示,科特里莫克萨PAP与传染性并发症之间没有显著的关联.
结论:
- 在TRPB中,当干预前查排除多耐药性格拉姆阴性时,对PAP而言,cotrimoxazole似乎是可行的和实用的.
- 这种方法为TRPB抗生素预防提供了诺基诺的潜在替代方案.
- 进一步的研究可能是有必要的,以确认长期的结果和抵抗模式.
相关概念视频
Pulmonary Tuberculosis V
178
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
178
Antibiotic Selection
53.3K
Overview
53.3K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Combined Effects of Drugs: Synergism
3.9K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.9K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
134
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
134


